Influence of Asparaginase on a Combination Chemotherapy Protocol for Canine Multicentric Lymphoma

Jeffreys, Antonella Borgatti; Knapp, Deborah W.; Carlton, William W.; Thomas, Rosanne M.; Bonney, Patty L.; DeGortari, Amalia E.; Lucroy, Michael D.

doi:10.5326/0410221

Cited by 43 publications

(41 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a majority of dogs in the MOPP group that received l-asparaginase, induction was performed with a combination of l-asparaginase and vincristine before moving on to a MOPP protocol, likely once T-cell immunophenotype was determined. In addition to the fact that l-asparaginase use was evaluated and found to be balanced between the groups, and it has been shown that l-asparaginase use does not significantly impact outcome including likelihood of remission or duration of progression-free interval, it is unlikely that it impacted the results in the current study (Jeffreys et al 2005, MacDonald et al 2005.…”

Section: Discussionmentioning

confidence: 83%

Comparison of combination l‐asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi‐centric T‐cell or hypercalcaemic lymphoma

Angelo

Cronin²,

Keys³

2019

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To compare the progression‐free survival of dogs with high‐grade T‐cell lymphoma treated with either a cyclophosphamide, doxorubicin, vincristine and prednisone‐based or a modified mechlorethamine, vincristine, prednisone and procarbazine chemotherapy protocol. Materials and Methods In this retrospective study, cases were selected based on histologic or cytologic diagnosis of lymphoma, T‐cell phenotype, hypercalcaemia, or both, and no previous chemotherapy for lymphoma. Treatment was not randomly allocated. Results Seventy‐three dogs were included in this study: 50 in the cyclophosphamide, doxorubicin, vincristine and prednisone group and 23 in the mechlorethamine, vincristine, prednisone and procarbazine group. The median progression‐free survival was 133 days for dogs in the cyclophosphamide, doxorubicin, vincristine and prednisone group and 97 days for dogs in the mechlorethamine, vincristine, prednisone and procarbazine group. When golden retrievers (n = 16) were evaluated separately, progression‐free survival was longer in the cyclophosphamide, doxorubicin, vincristine and prednisone versus mechlorethamine, vincristine, prednisone and procarbazine treatment group (median PFS 154 days versus 70.5 days, respectively). Clinical Significance The progression‐free survival time for dogs with multi‐centric T‐cell lymphoma treated with a modified mechlorethamine, vincristine, prednisone and procarbazine protocol was similar to that of dogs treated with cyclophosphamide, doxorubicin, vincristine and prednisone. Further studies, including those evaluating golden retrievers separately, are needed to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 83%

Comparison of combination l‐asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi‐centric T‐cell or hypercalcaemic lymphoma

Angelo

Cronin²,

Keys³

2019

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9] For patients in CR, various treatment strategies have been explored to eliminate minimal residual disease that could contribute to relapse. Such strategies included highdose chemotherapy with 10 or without 11 autologous bone marrow transplantation, standard-dose maintenance therapy, [1][2][3][4]6,9,12 chemoimmunotherapy, 13 half-body radiation therapy (HBRT), [14][15][16] or consolidation with new drug combinations. 17 The optimal dose, schedule, or number of cycles of maintenance or consolidation therapy for dogs who achieve CR has not been established.…”

mentioning

confidence: 99%

Comparison of 3 Protocols for Treatment after Induction of Remission in Dogs with Lymphoma

Rassnick¹,

McEntee²,

Erb³

et al. 2007

J Vet Int Med

View full text Add to dashboard Cite

Background: The optimal treatment after inducing complete remission (CR) in dogs with lymphoma has not been established. Hypothesis: After inducing CR with L-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisone (L-CHOP); consolidation with either half-body radiation therapy (HBRT); or lomustine (CCNU) and mechlorethamine, vincristine, procarbazine, prednisone (MOPP) would improve first remission duration compared with continuing a CHOP-based protocol for an additional 4 months.Animals: Dogs with stage III-V lymphoma.Methods: Prospective clinical trial in which dogs initially were treated with an 8-week induction protocol that consisted of L-CHOP. Dogs in CR after induction were then allocated to 1 of 2 consolidation arms. A chemotherapy consolidation arm consisted of 2 treatments with CCNU and 1 cycle of MOPP. A HBRT arm consisted of 2 sequential 8.0-Gy fractions to the cranial and caudal half-body separated by 30 days. Vincristine was given between fractions. Results of the consolidation arms also were compared with a historical group treated with the same 8-week induction protocol followed by CHOP therapy until week 24.Results: Overall, 67% of the dogs were in CR after 8 weeks of induction chemotherapy and were compared. Fifty-two dogs were in the historical arm, 23 in the CCNU/MOPP arm, and 27 in the HBRT arm. No difference in first remission duration was found among groups. Median first remission duration for the historical, CCNU/MOPP, and HBRT arms were 307, 274, and 209 days, respectively (P 5 .28). Overall second CR rate was 82% and was not different among groups (all P $ .58). Overall remission duration (P 5 .28) and survival time (P 5 .48) were not different among groups.Conclusions and Clinical Importance: Consolidation with either CCNU/MOPP or HBRT showed no advantage over a standard CHOP-based protocol.

show abstract

“…Canine malignant lymphoma is the most common haematopoietic cancer in dogs 16 . In this study, all three dogs were diagnosed with naturally occurring malignant lymphoma based on clinical presentation, physical examination and immunophenotyping.…”

Section: Discussionmentioning

confidence: 99%

“…Canine lymphoma is the most common naturally occurring haematopoietic tumour in dogs 16 . In the more aggressive or high grade forms of lymphomas, the most common finding is painless enlargement of one or more peripheral lymph nodes although many dogs can be asymptomatic upon presentation.…”

Section: Introductionmentioning

confidence: 99%

Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma

Wilson

Regnier

Knapp

et al. 2008

Vet Comparative Oncology

View full text Add to dashboard Cite

Differential expression of fucosylated glycoproteins has been correlated with malignancy and metastatic potential in various types of neoplasia. Utilizing glycoproteomics techniques, changes in fucosylated serum peptides associated with naturally occurring canine lymphoma and transitional cell carcinoma (TCC) have been evaluated. In both types of neoplasia, the majority of the fucosylated peptides that changed increased with the cancer. In one lymphoma case that was examined over the course of the disease, the same fucosylated peptides that increased during pre-chemotherapy decreased during post-chemotherapy, and then subsequently increased upon recurrence of the lymphoma. When comparing all the fucosylated peptides that increased in both types of cancer, there were only two peptides in common allowing discrimination between lymphoma and TCC based on their peptide profiles. These results emphasize the prospect of glycopeptide profiling in proteomics for use in discovering a panel of non-invasive, diagnostic or prognostic biomarkers of cancer.

show abstract

Influence of Asparaginase on a Combination Chemotherapy Protocol for Canine Multicentric Lymphoma

Cited by 43 publications

References 18 publications

Comparison of combination l‐asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi‐centric T‐cell or hypercalcaemic lymphoma

Comparison of combination l‐asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi‐centric T‐cell or hypercalcaemic lymphoma

Comparison of 3 Protocols for Treatment after Induction of Remission in Dogs with Lymphoma

Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma

Contact Info

Product

Resources

About